O Ukkola1, Y A Kesäniemi. 1. Department of Internal Medicine and Biocenter Oulu, University of Oulu, Oulu, Finland. olavi.ukkola@oulu.fi
Abstract
OBJECTIVES: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. DESIGN: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n=515) and control cohorts (n=525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. RESULTS: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio=3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. CONCLUSIONS: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels.
OBJECTIVES:Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. DESIGN: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n=515) and control cohorts (n=525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. RESULTS: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio=3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. CONCLUSIONS: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels.
Authors: Jerrold J Heindel; Bruce Blumberg; Mathew Cave; Ronit Machtinger; Alberto Mantovani; Michelle A Mendez; Angel Nadal; Paola Palanza; Giancarlo Panzica; Robert Sargis; Laura N Vandenberg; Frederick Vom Saal Journal: Reprod Toxicol Date: 2016-10-17 Impact factor: 3.143
Authors: Jonatan R Ruiz; Carmen Fiuza-Luces; Amaya Buxens; Amalia Cano-Nieto; Félix Gómez-Gallego; Catalina Santiago; Gabriel Rodríguez-Romo; Nuria Garatachea; José I Lao; María Morán; Alejandro Lucia Journal: Age (Dordr) Date: 2011-09-06
Authors: Brittany M Angle; Rylee Phuong Do; Davide Ponzi; Richard W Stahlhut; Bertram E Drury; Susan C Nagel; Wade V Welshons; Cynthia L Besch-Williford; Paola Palanza; Stefano Parmigiani; Frederick S vom Saal; Julia A Taylor Journal: Reprod Toxicol Date: 2013-07-25 Impact factor: 3.143
Authors: Stephan Schiekofer; Marcus E Kleber; Winfried Maerz; Franz M Rasche; Jochen G Schneider Journal: Int J Endocrinol Date: 2017-05-30 Impact factor: 3.257